On Mar. 26, 2024, Roche announced that the U.S. Food and Drug Administration (FDA) had approved the cobasﾮ Malaria test for use on the cobasﾮ 6800/8800 Systems. This approved test can aid healthcare professionals in reducing potential risks of patient infection from transfused blood products.

The cobas Malaria molecular test screens whole blood samples for the five main species of Plasmodium parasites that are known to cause human infection.